.png){kind=icon}
返回
Software supporting optimal experimental design: A case study of binary diffusion using EFCOSS
.png){kind=icon}
PRE
AI
DOI：10.1016/j.compchemeng.2008.12.008.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Methods for optimal experimental design aim at minimizing uncertainty in parameter estimation problems. Despite their long tradition in applied mathematics and importance in practical applications, they are currently not widely used in computational science and engineering. To make the techniques of optimal experimental design more accessible to a broader community, we introduce a novel software environment called EFCOSS and demonstrate its ease of use and versatility in two case studies of binary diffusion experiments. Through the use of a component-based software architecture, integration of automatic differentiation technology and facilitated interfacing to optimization algorithms. EFCOSS minimizes the computational overhead for the user who can thus focus on model development and analysis itself. The presented case studies focus on diffusion experiments in liquids since these experiments are typically very demanding. The use of optimal experimental design techniques allows to reduce experimental time and effort significantly. (C) 2009 Elsevier Ltd. All rights reserved.
Keyword:
Optimal experimental design
Parameter estimation
EFCOSS
Diffusion experiment
Distributed computing
Automatic differentiation
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
C
IF:
3.9
论文数:
8.1K
被引数:
1.7W
机构
引用论文
Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico.png)
Hematology
OAAI
HematologyIF0
OAAI分享收藏Microsomal Cytochrome P450 Dependent Oxidation of N-Hydroxyguanidines, Amidoximes, and Ketoximes: Mechanism of the Oxidative Cleavage of Their CN(OH) Bond with Formation of Nitrogen OxidesN-羟基胍，偕胺肟和酮肟的微粒体细胞色素P450依赖性氧化: 其CN(OH) 键氧化裂解并形成氮氧化物的机理Biochemistry
BiochemistryIF0
PREAI
分享收藏Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access studyLung Cancer
Lung CancerIF0
PREAI
分享收藏
查看更多内容